ELELYSO
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ELELYSO (ELELYSO).
Recombinant human glucocerebrosidase; hydrolyzes glucocerebroside to glucose and ceramide, reducing accumulated glucocerebroside in lysosomes of macrophages.
| Metabolism | Metabolized via peptide hydrolysis into small peptides and amino acids; not dependent on CYP450 enzymes. |
| Excretion | Primarily catabolized via peptide hydrolysis; renal excretion of small peptide fragments and amino acids; less than 1% excreted unchanged in urine. |
| Half-life | Mean terminal elimination half-life ranges from 6.1 to 8.9 minutes after intravenous infusion; rapid clearance due to receptor-mediated uptake. |
| Protein binding | Approximately 66% bound to plasma proteins, primarily to albumin and immunoglobulins. |
| Volume of Distribution | Central volume of distribution 0.02 L/kg; steady-state volume of distribution 0.04 to 0.06 L/kg, indicating primarily intravascular distribution. |
| Bioavailability | Not applicable; ELELYSO is administered intravenously; bioavailability is 100% by the IV route. |
| Onset of Action | Intravenous infusion: clinical effect observed within 30 minutes; peak reduction of glucosylceramide occurs 1-2 hours post-infusion. |
| Duration of Action | Intravenous infusion: symptomatic improvement lasts 2 to 4 weeks; recommended dosing interval is every 2 weeks. |
60 U/kg administered intravenously over 60 minutes every 2 weeks.
| Dosage form | POWDER |
| Renal impairment | No dosage adjustment required for renal impairment. Not studied in patients with CrCl < 30 mL/min. |
| Liver impairment | No dosage adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not studied in severe hepatic impairment (Child-Pugh C). |
| Pediatric use | For patients aged 4-17 years: 60 U/kg intravenously over 60 minutes every 2 weeks. |
| Geriatric use | Specific studies not conducted; follow adult dosing. Consider age-related changes in renal function and comorbidities. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ELELYSO (ELELYSO).
| Breastfeeding | No data available on presence in human milk; M/P ratio not established. Endogenous glucocerebrosidase is likely present in breast milk, but exogenous enzyme is not expected to achieve significant systemic levels in the infant due to gastrointestinal degradation. Caution advised. |
| Teratogenic Risk | First trimester: no evidence of human teratogenicity based on limited data from case reports and postmarketing surveillance; animal studies show no fetal harm at clinically relevant doses. Second and third trimesters: no reported adverse fetal outcomes; theoretical risk of placental transfer is low due to high molecular weight (recombinant protein). |
■ FDA Black Box Warning
None
| Serious Effects |
Life-threatening hypersensitivity (e.g., anaphylaxis) to the active substance or any excipients
| Precautions | Hypersensitivity reactions including anaphylaxis; immune complex-mediated reactions; thrombotic complications in patients with central venous catheters; monitoring for pulmonary hypertension; risk of cardiovascular events in patients with pre-existing cardiac disease. |
| Food/Dietary | Grapefruit and grapefruit juice may increase taliglucerase alfa exposure; avoid concurrent consumption. No other significant food interactions reported. |
| Clinical Pearls |
Loading safety data…
| Fetal Monitoring | Monitor maternal hematologic parameters (hemoglobin, platelet count) and organomegaly (liver and spleen size) during pregnancy; fetal ultrasound for growth and anatomy as per standard obstetric care; no specific fetal drug monitoring required. |
| Fertility Effects | No known effects on fertility in humans; animal studies did not show impaired fertility at clinically relevant doses. |
| ELELYSO (taliglucerase alfa) is a recombinant glucocerebrosidase enzyme replacement therapy for Gaucher disease type 1. Monitor for hypersensitivity reactions (including anaphylaxis) during infusion. Premedication with antihistamines and/or corticosteroids may be needed. Adjust dose based on clinical response and biomarkers (chitotriosidase, ACE). Not indicated for neuromopathic Gaucher disease (types 2 and 3). |
| Patient Advice | ELELYSO is given as an intravenous infusion every 2 weeks. · Common side effects include headache, fatigue, and allergic reactions (hives, rash, itching). · Contact your doctor immediately if you experience signs of an allergic reaction: difficulty breathing, swelling, severe rash. · Avoid eating grapefruit or drinking grapefruit juice during treatment as it may affect drug levels. · Inform your healthcare provider of all medications, including over-the-counter drugs and supplements. |